Business
Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test
MINNEAPOLIS and LOS ANGELES, May 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D
About this update from Bio-techne Corp
[{"type":"text","content":"MINNEAPOLIS and LOS ANGELES, May 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology.\nOncuria is the first-of-its-kind multiplex protein-based urine test to provide early and accurate detection, therapy choice, and disease monitoring of bladder cancer. The Luminex-based multiplex assay panel combines Bio-Techne's high-quality reagents and over 40 years of industry-leading immunoassay experience with Nonagen's diagnostic expertise to create a powerful solution to advance bladder cancer treatment strategies. The partnership demonstrates Bio-Techne's commitment to supporting laboratory developed tests (LDTs) to bring clinical diagnostic tools to the market.\nNonagen Bioscience and Bio-Techne are targeting the last quarter of calendar 2022 to make Oncuria available as an LDT.\nThe US Food and Drug Administration (FDA) granted Oncuria a Breakthrough Device Designation in September 2021, for predicting response to Bacillus Calmette-Guérin (BCG) therapy, a first-line treatment for bladder cancer. The designation enables close collaboration with, and expedited review of the assay by the FDA. It also provides formal acknowledgement of Oncuria's utility and potential clinical benefit.\n\"We're excited to partner with Bio-Techne to make Oncuria available as a laboratory developed test (LDT), given their extensive biomarker discovery expertise,\" said Nonagen Bioscience CEO Charles Joel Rosser, MD, MBA. \"Bio-Techne also shares our passion for translating research discoveries into innovative diagnostics, to improve the detection and management of cancer.\"\n\"We look forward to working with Nonagen to develop this game-changing immunoassay in the fight against bladder cancer,\" said Will Geist, President of Bio-Techne's Protein Sciences division. \"Nonagen's deep experience in diagnostic and testing research is complementary to Bio-Techne's extensive immunoassay expertise and world-class manufacturing capabilities, creating an ideal partnership for this important bladder cancer detection assay.\"\nAbout Bladder CancerAs the 6th most common cancer in the United States1 and a highly recurrent disease, bladder cancer is a majo...